0001683168-22-002526.txt : 20220412 0001683168-22-002526.hdr.sgml : 20220412 20220412095719 ACCESSION NUMBER: 0001683168-22-002526 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220412 DATE AS OF CHANGE: 20220412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNBX Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001343009 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203373669 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52403 FILM NUMBER: 22821315 BUSINESS ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 877-424-2429 MAIL ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: Cannabics Pharmaceuticals Inc. DATE OF NAME CHANGE: 20140620 FORMER COMPANY: FORMER CONFORMED NAME: American Mining Corp DATE OF NAME CHANGE: 20110510 FORMER COMPANY: FORMER CONFORMED NAME: Thrust Energy Corp. DATE OF NAME CHANGE: 20051031 10-Q 1 cnbx_i10q-022822.htm FORM 10-Q
0001343009 false --08-31 2022 Q2 0001343009 2021-09-01 2022-02-28 0001343009 2022-04-12 0001343009 2022-02-28 0001343009 2021-08-31 0001343009 2021-12-01 2022-02-28 0001343009 2020-12-01 2021-02-28 0001343009 2020-09-01 2021-02-28 0001343009 us-gaap:CommonStockMember 2021-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001343009 CNBX:WarrantsMember 2021-08-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001343009 us-gaap:RetainedEarningsMember 2021-08-31 0001343009 us-gaap:CommonStockMember 2021-11-30 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001343009 CNBX:WarrantsMember 2021-11-30 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-30 0001343009 us-gaap:RetainedEarningsMember 2021-11-30 0001343009 2021-11-30 0001343009 us-gaap:CommonStockMember 2020-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-08-31 0001343009 CNBX:WarrantsMember 2020-08-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-31 0001343009 us-gaap:RetainedEarningsMember 2020-08-31 0001343009 2020-08-31 0001343009 us-gaap:CommonStockMember 2020-11-30 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001343009 CNBX:WarrantsMember 2020-11-30 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-11-30 0001343009 us-gaap:RetainedEarningsMember 2020-11-30 0001343009 2020-11-30 0001343009 us-gaap:CommonStockMember 2021-09-01 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2022-02-28 0001343009 CNBX:WarrantsMember 2021-09-01 2022-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-01 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2021-09-01 2022-02-28 0001343009 us-gaap:CommonStockMember 2021-12-01 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-02-28 0001343009 CNBX:WarrantsMember 2021-12-01 2022-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-01 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2021-12-01 2022-02-28 0001343009 us-gaap:CommonStockMember 2020-09-01 2021-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-09-01 2021-02-28 0001343009 CNBX:WarrantsMember 2020-09-01 2021-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-01 2021-02-28 0001343009 us-gaap:RetainedEarningsMember 2020-09-01 2021-02-28 0001343009 us-gaap:CommonStockMember 2020-12-01 2021-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-12-01 2021-02-28 0001343009 CNBX:WarrantsMember 2020-12-01 2021-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-01 2021-02-28 0001343009 us-gaap:RetainedEarningsMember 2020-12-01 2021-02-28 0001343009 us-gaap:CommonStockMember 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001343009 CNBX:WarrantsMember 2022-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2022-02-28 0001343009 us-gaap:CommonStockMember 2021-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001343009 CNBX:WarrantsMember 2021-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-02-28 0001343009 us-gaap:RetainedEarningsMember 2021-02-28 0001343009 2021-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________

 

FORM 10-Q

_______________

 

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 28, 2022

 

OR

 

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______.

 

Commission File Number: 000-52403

___________________________________________________

 

CNBX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

___________________________________________________

 

Nevada   46-5644005

(State or other jurisdiction of

incorporation or organization)

   (IRS Employer Identification No.)
     

#3 Bethesda Metro Center, Suite 700

Bethesda, MD

   20814
(Address of principal executive offices)   (Zip Code)

 

(877) 424-2429

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Act:

Title of each class Name of each exchange on which registered
N/A N/A

 

Securities registered under Section 12(g) of the Act:

Common Stock, $.0001 Par Value

(Title of class)

_____________________________________________________

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No  ☐ 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒ No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer  ☐ Accelerated filer  ☐
Non-accelerated filer  ☒ Smaller reporting company  ☒
  Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No  ☒

 

As of April 12, 2022, the registrant had 149,436,681 shares of its Common Stock, $0.0001 par value, outstanding.

 

When used in this quarterly report, the terms “CNBX,” “the Company,” “we,” “our,” and “us” refer to CNBX Pharmaceuticals Inc. and its wholly-owned subsidiaries, G.R.I.N Ultra Ltd. and Digestix Bioscience Inc.

 

 

   

 

 

CNBX PHARMACEUTICALS INC.

FORM 10-Q

FEBRUARY 28, 2022

 

INDEX

 

Cautionary Note Regarding Forward-Looking Statements 3
   
PART I – FINANCIAL INFORMATION 4
     
Item 1. Consolidated Financial Statements 4
  Consolidated Balance Sheets as of February 28, 2022 (unaudited) and August 31, 2021 4
  Consolidated Statements of Operations for the Three and Six Months Ended February 28, 2022 and February 28, 2021 (unaudited) 5
  Consolidated Statements of Stockholder’s Equity for the Three and Six Months Ended February 28, 2022 and February 28, 2021 (unaudited) 6
  Consolidated Statements of Cash Flows for the Six Months Ended February 28, 2022 and February 28, 2021 (unaudited) 8
  Notes to Consolidated Financial Statements (unaudited) 9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 3. Quantitative and Qualitative Disclosures About Market Risk 16
Item 4. Controls and Procedures 16
     
PART II – OTHER INFORMATION 18
     
Item 1. Legal Proceeding 18
Item 1A. Risk Factors 18
Item 2. Recent Sale of Unregistered Securities 18
Item 6. Exhibits 18
     
SIGNATURE 19

 

 

 2 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

 

  · the size and growth of the potential markets for our products and the ability to serve those markets;
     
  · our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;
     
  · the rate and degree of market acceptance of any of our products;
     
  · our expectations regarding competition;
     
  · our anticipated growth strategies;
     
  · our ability to attract or retain key personnel;
     
  · our ability to establish and maintain development partnerships;
     
  · regulatory developments in the U.S. and foreign countries, especially those related to change in, and enforcement of, cannabis laws;
     
  · our ability to obtain and maintain intellectual property protection for our products; and
     
  · the anticipated trends and challenges in our business and the market in which we operate.

 

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended August 31, 2021 (filed on November 29th, 2021) entitled “Risk Factors” as well as in our other public filings.

 

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

 

 

 

 4 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

  

CNBX PHARMACEUTICALS INC.

Consolidated Balance Sheets

 

 

   February 28,   August 31, 
   2022   2021 
ASSETS          
           
Current assets:          
Cash and cash equivalents  $231,637   $1,386,472 
Prepaid expenses and other receivables   167,958    204,375 
Total current assets   399,595    1,590,847 
           
Available for sale Investment   197,217    845,218 
           
Equipment, net   540,998    642,896 
           
Total assets  $1,137,810   $3,078,961 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
Current liabilities:          
Accounts payable and accrued liabilities  $237,193   $177,505 
Convertible loan   1,325,000    871,896 
Due to a related party   223,645    223,645 
Total current liabilities   1,785,838    1,273,046 
           
Stockholders' equity (deficit):          
Preferred stock, $.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding   –    – 
Common stock, $.0001 par value, 900,000,000 shares authorized, 149,436,681 and 148,661,247 shares issued and outstanding at February 28, 2022 and August 31, 2021 respectively   14,715    14,475 
Additional paid-in capital   17,819,072    17,063,363 
Issuance of warrants   3,459,510    3,459,510 
Other comprehensive loss   (2,553,716)   (1,905,715)
Accumulated deficit   (19,387,609)   (16,825,718)
Total stockholders' equity (deficit)   (648,028)   1,805,915 
           
Total liabilities and stockholders' equity  $1,137,810   $3,078,961 

 

See accompanying notes to consolidated financial statements.

 

 

 5 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

 

                 
   For the Three Months Ended   For the Six Months Ended 
   February 28,   February 28,   February 28,   February 28, 
   2022   2021   2022   2021 
                 
Operating expenses:                    
Research and development expense   330,576    315,958    770,620    749,688 
General and administrative expenses   399,685    351,911    1,069,990    577,913 
                     
Total operating expenses   730,261    667,869    1,840,610    1,327,601 
                     
Loss from operations   (730,261)   (667,869)   (1,840,610)   (1,327,601)
                     
Other income (loss)                    
Capital gain   –    195,968    –    195,968 
Financial Loss, net.   (508,610)   (62,854)   (721,280)   (57,889)
                     
Net (loss)   (1,238,871)   (534,755)   (2,561,891)   (1,189,522)
                     
Profit (loss) from available for sale assets   (366,790)   2,622,133    (648,001)   2,735,220 
Total comprehensive income (loss)  $(1,605,661)  $2,087,378   $(3,209,892)  $1,545,698 
                     
Net loss per share - basic and diluted:  $(0.008)  $0.004   $(0.02)  $0.01 
                     
Weighted average number of shares outstanding - Basic and Diluted   147,142,263    135,237,584    146,304,758    135,235,838 

 

 

 

See accompanying notes to consolidated financial statements.

 

 

 6 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Stockholder’s Equity

(Unaudited)

 

 

For the six months ended February 28, 2022

 

                                    
   Common Stock   Additional Paid In       Other Comprehensive   Accumulated   Total Stockholders’ Equity 
   Shares   Amount   Capital   Warrants   Gain   Deficit   (Deficit) 
                             
Balance, August 31, 2021   144,747,584   $14,475   $17,063,363   $3,459,510   $(1,905,715)  $(16,825,718)  $1,805,915 
                                    
Share based payment   –    –    530,662    –    –    –    530,662 
                                    
Exercise of CLA to shares   2,403,294    240    225,047    –    –    –    225,287 
                                    
Other comprehensive loss   –    –    –    –    (648,001)   –    (648,001)
                                    
Net loss   –    –    –    –    –    (2,561,891)   (2,561,891)
                                    
Balance, February 28, 2022   147,150,878   $14,715   $17,819,072   $3,459,510   $(2,553,716)  $(19,387,609)  $(648,028)

 

 

For the three months ended February 28, 2022

 

   Common Stock   Additional Paid In       Other Comprehensive   Accumulated   Total Stockholders’ Equity 
   Shares   Amount   Capital   Warrants   Gain   Deficit   (Deficit) 
                             
Balance, November 30, 2021   156,375,444   $14,637   $17,664,225   $3,459,510   $(2,186,926)  $(18,148,738)  $802,708 
                                    
Share based payment   –    –    104,925    –    –    –    104,925 
                                    
Exercise of CLA to shares   778,434    78    49,922    –    –    –    50,000 
                                    
Other comprehensive loss   –    –    –    –    (366,790)   –    (366,790)
                                    
Net loss   –    –    –    –    –    (1,238,871)   (1,238,871)
                                    
Balance, February 28, 2022   147,150,878   $14,715   $17,819,072   $3,459,510   $(2,553,716)  $(19,387,609)  $(648,028) 

 

 

 7 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Stockholder’s Equity

(Unaudited)

 

 

For the six months ended February 28, 2021

 

   Common stock   Additional paid in       Unrealized gain (loss) on available-for-sale financial   Accumulated   Total stockholders’ equity 
   Shares   Amount   capital   Warrants   gain   deficit   (deficit) 
                             
Balance, August 31, 2020   135,080,441   $13,508   $15,372,311   $2,784,387   $(2,774,411)  $(13,631,271)  $1,764,524 
                                    
Issuance of common stock for services, net.   157,143    16    32,984    –    –    –    33,000 
                                    
Issuance of warrants   –    –    –    439,330    –    –    439,330 
                                    
Other comprehensive income   –    –    –    –    2,735,220    –    2,735,220 
                                    
Net loss   –    –    –    –    –    (1,189,522)   (1,189,522)
                                    
Balance, February 28, 2021   135,237,584   $13,524   $15,405,295   $3,223,717   $(39,191)  $(14,820,793)  $3,782,552 

 

 

For the three months ended February 28, 2021

 

   Common stock   Additional paid in       Unrealized gain (loss) on available-for-sale financial   Accumulated   Total stockholders’ equity 
   Shares   Amount   capital   Warrants   gain   deficit   (deficit) 
                             
Balance, November 30, 2020   135,237,584   $13,524   $15,405,295   $2,784,387   $(2,661,324)  $(14,286,038)  $1,255,844 
                                    
Issuance of warrants   –    –    –    439,330    –    –    439,330 
                                    
Other comprehensive income   –    –    –    –    2,622,133    –    2,622,133 
                                    
Net loss   –    –    –    –    –    (534,755)   (534,755)
                                    
Balance, February 28, 2021   135,237,584   $13,524   $15,405,295   $3,223,717   $(39,191)  $(14,820,793)  $3,782,552 

 

 

 

 8 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Cash Flows

(Unaudited)

 

 

           
   For the Six month Ended 
   February 28,   February 28, 
   2022   2021 
Cash flows from operating activities:          
Net (Loss)  $(2,561,891)  $(1,189,522)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Depreciation   102,411    114,007 
Capital gain   –    (195,968 
Royalties receivables valuation   –    – 
Stock issued for services   –    33,000 
Profit from held for trading investments   –    – 
Changes in operating assets and liabilities:          
Convertible loan valuation   678,391    – 
Share based payment   530,662    – 
Accounts Receivable and pre paid expenses   36,417    (18,294)
Accounts payable and accrued liabilities   59,688    (38,200)
Net cash used in operating activities   (1,154,322)   (1,294,977)
           
Cash flows from investing activities:          
Realization of Available for sale investment   –    645,968 
Held for trading Investments   –    – 
Acquisition of equipment   (513)   (943)
Net cash from (used) in investing activities   (513)   645,025 
           
Cash flows from financing activities:          
Proceeds from convertible loan agreement   –    1,206,750 
Net cash provided by financing activities   –    1,206,750 
           
Net increase (Decrease) in cash   (1,154,835)   556,798 
Cash and cash equivalents at beginning of the Period   1,386,472    777,611 
Cash and cash equivalents at end of the Period  $231,637   $1,334,409 

 

 

See accompanying notes to consolidated financial statements.

  

 

 9 

 

 

CNBX PHARMACEUTICALS INC.

Notes to Consolidated Financial Statements

(Unaudited)

 

 

Note 1– Nature of Business, Presentation and Going Concern

 

Organization

 

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.

 

On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.

 

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

 

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

 

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

 

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

 

On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.

 

On August 20th, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including in-vivo experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.

  

On October 18th, 2021, the Company filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.

 

On February 13th, 2022, the company established a Nomination and Governance Committee.

 

 

 

 

 10 

 

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited financial statements should be read in conjunction with our August 31, 2021 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 29th, 2021.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Going Concern

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $2,561,891 for the six months ended February 28, 2022, it has incurred cumulative losses since inception of $19,387,609. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

 

Research and Development Costs

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $770,620 and $749,688 for the six months ended February 28, 2022 and 2021, respectively.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

 

Note 2 – Related Party Transactions

 

During the six months ending February 28, 2022, the Company paid $244,920 in salaries, including socials benefits, to two directors, compared to $248,763 for the six months ending February 28, 2021.

 

During the six months ending February 28, 2022, the Company recorded a non cash expense of $530,662 in share based payment, to the company chairman, board members and advisor, compared to non for the six months ending February 28, 2021.

 

The Company had a balance outstanding on February 28, 2022 and at February 28, 2021 of $223,645, payable to Cannabics, Inc. The advance is due on demand and bears no interest.

 

 

 

 

 11 

 

 

Note 3 – Stockholders’ Equity (Deficit)

 

Authorized Shares

 

The Company is authorized to issue up to 900,000,000 shares of common stock, par value $0.0001 per share. There is also 100,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

 

Note 4 – Commitments and Contingencies

 

We lease the property of our corporate office in Tel Aviv, the monthly lease is $3,500, our current lease expires June 30th, 2022. The management intend to execute a lease agreement by that time for an additional year.

 

We lease the property of our laboratory in Rehovot, Israel, the monthly lease is $6,500 per month. Our current lease terminates at the end of February 2024, though we have a two additional one-year option, which management intends to execute prior to that time.

 

As security for its obligation under a property lease agreement, car lease and credit cards, the Company’s subsidiary provided a bank guarantee in the amount of $50,000.

 

Note 5 – Major Events During the six months ended on February 28, 2022

 

On February 4th, 2022, the Company filed a Pre-14C Information Statement with the SEC.

 

On February 15th, 2022 the Company filed its Definitive 14-C Information Statement with the SEC.

 

On February 17th, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement with an institutional investor.

 

On February 18th, 2022, the Company filed an S-1 Registration Statement with the SEC.

 

During the six months ended February 28, 2022, the Company issued 2,403,294 shares of its common stock to an investor as a result of a convertible loan exercise in the sum of $225,228.

 

Note 6 – Subsequent Events

 

On March 16th, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement as well as demand promissory note from an institutional investor in the principal amount of $280,000 with an original issue discount of $40,000.

 

The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum.

 

On March 28th, 2022, the Company filed an 8K with the SEC giving notice of its formal name change to “CNBX Pharmaceuticals Inc.”

 

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no such events that warrant disclosure or recognition in the financial statements.

 

 

 

 

 

 

 12 

 

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Company Overview

 

We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ("CRC"). Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in colon cancer patients as a standalone in neoadjuvant treatment or "window of opportunity" at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company hopes to start first in human Phase I/II clinical trials in 2023. Neoadjuvant treatment is the administration of a therapy before the surgical treatment to improve patient outcome, and our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development.

 

Results of Operations

 

For the Three Months Ended February 28, 2022 and 2021

  

Operating Expenses

 

For the three months ended February 28, 2022, our total operating expenses were $730,261 compared to $667,869 for the three months ended February 28, 2021, resulting in an increase of $62,392. The increase is attributable to a total decrease of $47,774 in general administration, and sales and marketing expenses and an increase of $14,618 in research and development expenses.

 

We realized other loss of $508,610 for the three months ended February 28, 2022, compared to other income of $133,114 for the three months ended February 28, 2021. The increase in financial expense was mainly attributable to convertible loan valuation of $481,624 and exchange differences in total of $26,900. As a result, the net loss was $1,238,871 for the three months ended February 28, 2022, compared to a net loss of $534,755 for the three months ended February 28, 2021.

 

Net Loss

 

Net loss for the three months ended February 28, 2022 was $1,238,871 compared to net loss $534,755 for the three months ended February 28, 2021, for the reasons explained above.

  

Other comprehensive profit

 

We incurred another comprehensive loss of $366,790 for the three months ended February 28, 2022. The loss was due to a valuation of a financial asset, consisting of the Company’s shares held in Sativus Inc (previously Seedo Inc), as a result; the total comprehensive loss was $1,605,661 for the three months ended February 28, 2022.

 

 

 

 13 
 

 

For the Six Months Ended February 28, 2022 and 2021

 

Operating Expenses

 

For the six months ended February 28, 2022, our total operating expenses were $1,840,610 compared to $1,327,601 for the six months ended February 28, 2021, resulting in an increase of $513,009. The increase is attributable to a total increase of $492,077 in general administration, and sales and marketing expenses and increase of $20,932 in research and development expenses.

 

We realized finance expenses of $721,280 for the six months ended February 28, 2022, which mainly attributable to convertible loan valuation of $678,392 and exchange differences in total of $42,256 and. Compared to other income of $138,079 for the six months ended February 28, 2021. As a result, the net loss was $2,561,891 for the six months ended February 28, 2022, compared to a net loss of $1,189,522 for the six months ended February 28, 2021. 

 

Net loss

 

Net loss for the six months ended February 28, 2022 was $2,561,891 compare to net loss of $1,189,522 for the six months ended February 28, 2022.

 

Other comprehensive profit

 

We incurred another comprehensive loss of $648,001 for the six months ended February 28, 2022. The loss was mainly attributable to a revaluation of a financial asset, consisting of the Company’s shares held in Sativus (previously Seedo), in the total amount of $648,001 As a result; the total comprehensive loss was $3,209,892 for the six months ended February 28, 2022.

 

Liquidity and Capital Resources

 

Overview

 

As of February 28, 2022, we had $231,637 in cash compared to $1,386,472 on August 31, 2021. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.

 

 

 

 14 
 

 

Liquidity and Capital Resources during the Six Months Ended February 28, 2022 compared to the Six Months Ended February 28, 2021

 

We used cash in operations of $1,154,322 for the six months ended February 28, 2022 compared to cash used in operations of $1,294,977 for the six months ended February 28, 2021. The negative cash flow from operating activities for the six months ended February 28, 2022 is primarily attributable to the Company's net loss from operations of $2,561,891, share based compensation of $530,662, convertible loan valuation in a total of $678,391, depreciation of $102,411, a decrease in accounts payables and accrued liabilities of $36,47 and an increase of $59,688 in account receivables and prepaid expenses.

 

We had cash used from investing activities of $513 during the six months ended February 28, 2022, compared to cash flow from investing activities of $645,025 for the six months ended February 28, 2021. The cash used to purchase of fixed assets in the aggregate amount of $513 for the six months ended February 28, 2022, comparing to cash flow from investing activities is due to the Company’s Realization of Wize Pharma Inc shares of $645,968 and its purchase of fixed assets in the aggregate amount of $943 for the six months ended February 28, 2021

 

We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.

 

Going Concern

 

Our independent auditors included an explanatory paragraph in their report on the accompanying unaudited financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

 

Our unaudited financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

 

There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

 

Off-Balance Sheet Arrangements

 

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

 

 

 

 15 
 

 

Critical Accounting Policies

   

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

 

See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2, “Summary of Significant Accounting Policies” in our audited consolidated financial statements for the year ended August 31, 2021, included in our Annual Report on Form 10-K as filed on November 29th, 2021, for a discussion of our critical accounting policies and estimates.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

The disclosure required under this item is not required to be reported by smaller reporting companies; as such term is defined by Item 503(e) of Regulation S-K.

 

Item 4. Controls and Procedures.

 

  (a) Evaluation of Disclosure Controls and Procedures

 

The Company maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including its Chief Executive Officer, Chief Financial Officer and the full Audit Committee, of the effectiveness of its disclosure controls and procedures. The Audit Committee assessed, reviewed and determined that the Company’s disclosure controls and procedures were effective as to this quarterly filing. Based on that evaluation, The Board accepted and ratified the findings of the Audit Committee that the Company’s disclosure controls and procedures, as of November 30th, 2021, the end of the period covered by this Quarterly Report on Form 10-Q, were effective to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer, Chief Financial Officer, and Audit Committee as appropriate to allow timely decisions regarding required disclosure.

 

 

 

 16 
 

 

 

  (b) Changes in Internal Control over Financial Reporting

 

 Since our annual report, the Company has maintained an Audit Committee to better review our internal financial reporting. There were no other changes in our internal control over financial reporting during the period ending February 28th, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

  (c) Limitations on the Effectiveness of Internal Controls

 

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

  

 

 

 

 

 

 

 

 17 

 

 

PART II- OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 2. Recent Sale of Unregistered Securities

 

None.

 

Item 6. Exhibits

 

Exhibit 31.1* Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
   
Exhibit 31.2* Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
   
Exhibit 32.1** Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
Exhibit 32.2** Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
101.INS*** Inline XBRL Instance Document
101.SCH*** Inline XBRL Taxonomy Extension Schema Document
101.CAL*** Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*** Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*** Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*** Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

______________________________

* Filed herewith.
   
** Furnished herewith.
   
*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 

 18 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CNBX Pharmaceuticals Inc.
     
Date: April 12, 2022 By: /s/ Eyal Barad
    Eyal Barad
  Title:

Chief Executive Officer

(Principal Executive Officer)

     
     
Date: April 12, 2022 By: /s/ Uri Ben Or
    Uri Ben Or
  Title:

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 19 

 

 

 EX-31.1 2 cnbx_ex3101.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Eyal Barad, certify that:

 

1. I have reviewed this Form 10-Q of CNBX PHARMACEUTICALS INC.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
     
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: April 12, 2022 By: /s/ Eyal Barad  
    Eyal Barad  
   

Director, Chief Executive Officer

CNBX PHARMACEUTICALS INC.

  
 EX-31.2 3 cnbx_ex3102.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Uri Ben Or, certify that:

 

1. I have reviewed this Form 10-Q of CNBX PHARMACEUTICALS INC.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
     
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: April 12, 2022 By: /s/ Uri Ben Or  
    Uri Ben Or  
   

Chief Financial Officer

CNBX PHARMACEUTICALS INC.

  
 EX-32.1 4 cnbx_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with this Quarterly Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-Q for the quarter ending February 28, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Eyal Barad, Director and Chief Executive Officer (Principal Executive Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. Such Quarterly Report on Form 10-Q for the quarter ending February 28, 2022, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending February 28, 2022, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

       
Date: April 12, 2022 By: /s/ Eyal Barad  
    Eyal Barad  
   

Director, Chief Executive Officer

CNBX PHARMACEUTICALS INC.

  
       
 EX-32.2 5 cnbx_ex3202.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-Q for the quarter ending February 28, 2022, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Uri Ben Or, Chief Financial Officer (Principal Financial Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. Such Quarterly Report on Form 10-Q for the quarter ending February 28, 2022, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending February 28, 2022, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: April 12, 2022 By: /s/ Uri Ben Or  
    Uri Ben Or  
   

Chief Financial Officer

CNBX PHARMACEUTICALS INC.

  
       
 EX-101.SCH 6 cnbx-20220228.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business, Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 – Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Major Events During the six months ended on February 28, 2022 link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Nature of Business, Presentation and Going Concern (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Major Events During the six months ended on February 28, 2022 (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cnbx-20220228_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cnbx-20220228_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cnbx-20220228_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Warrants [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expenses and other receivables Total current assets Available for sale Investment Equipment, net Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities Convertible loan Due to a related party Total current liabilities Stockholders' equity (deficit): Preferred stock, $.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding Common stock, $.0001 par value, 900,000,000 shares authorized, 149,436,681 and 148,661,247 shares issued and outstanding at February 28, 2022 and August 31, 2021 respectively Additional paid-in capital Issuance of warrants Other comprehensive loss Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Outstanding Preferred Stock, Shares Issued Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Outstanding Common Stock, Shares, Issued Income Statement [Abstract] Operating expenses: Research and development expense General and administrative expenses Total operating expenses Loss from operations Other income (loss) Capital gain Financial Loss, net. Net (loss) Profit (loss) from available for sale assets Total comprehensive income (loss) Net loss per share - basic and diluted: Weighted average number of shares outstanding - Basic and Diluted Statement [Table] Statement [Line Items] Beginning balance, value Shares, Outstanding, Beginning Balance Share based payment Exercise of CLA to shares Stock Issued During Period, Shares, Conversion of Convertible Securities Other comprehensive income Net loss Issuance of common stock for services, net. Stock Issued During Period, Shares, Issued for Services Issuance of warrants Ending balance, value Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] Cash flows from operating activities: Net (Loss) Adjustments required to reconcile net loss to net cash used in operating activities: Depreciation Capital gain Royalties receivables valuation Stock issued for services Profit from held for trading investments Changes in operating assets and liabilities: Convertible loan valuation Share based payment Accounts Receivable and pre paid expenses Accounts payable and accrued liabilities Net cash used in operating activities Cash flows from investing activities: Realization of Available for sale investment Held for trading Investments Acquisition of equipment Net cash from (used) in investing activities Cash flows from financing activities: Proceeds from convertible loan agreement Net cash provided by financing activities Net increase (Decrease) in cash Cash and cash equivalents at beginning of the Period Cash and cash equivalents at end of the Period Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business, Presentation and Going Concern Related Party Transactions [Abstract] Related Party Transactions Equity [Abstract] Stockholders’ Equity (Deficit) Commitments and Contingencies Disclosure [Abstract] Note 4 – Commitments and Contingencies Major Events During Six Months Ended On February 28 2022 Major Events During the six months ended on February 28, 2022 Subsequent Events [Abstract] Subsequent Events Basis of Presentation Principles of Consolidation Going Concern Research and Development Costs Stockholders' Equity, Reverse Stock Split Net Income (Loss) Attributable to Parent Retained Earnings (Accumulated Deficit) Research and Development Expense Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Share-based Payment Arrangement, Noncash Expense Due to Related Parties, Current Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Amount Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Nonoperating Expense Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Adjustments to Additional Paid in Capital, Warrant Issued Increase (Decrease) in Other Receivables Gain (Loss) on Investments Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Machinery and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents EX-101.PRE 10 cnbx-20220228_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
 6 Months Ended
Feb. 28, 2022
Apr. 12, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Feb. 28, 2022  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --08-31  
Entity File Number 000-52403  
Entity Registrant Name CNBX PHARMACEUTICALS INC.  
Entity Central Index Key 0001343009  
Entity Tax Identification Number 46-5644005  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One #3 Bethesda Metro Center  
Entity Address, Address Line Two Suite 700  
Entity Address, City or Town Bethesda  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20814  
City Area Code (877)  
Local Phone Number 424-2429  
Title of 12(g) Security Common Stock, $.0001 Par Value  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   149,436,681
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Feb. 28, 2022
Aug. 31, 2021
Current assets:    
Cash and cash equivalents $ 231,637 $ 1,386,472
Prepaid expenses and other receivables 167,958 204,375
Total current assets 399,595 1,590,847
Available for sale Investment 197,217 845,218
Equipment, net 540,998 642,896
Total assets 1,137,810 3,078,961
Current liabilities:    
Accounts payable and accrued liabilities 237,193 177,505
Convertible loan 1,325,000 871,896
Due to a related party 223,645 223,645
Total current liabilities 1,785,838 1,273,046
Stockholders' equity (deficit):    
Preferred stock, $.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding 0 0
Common stock, $.0001 par value, 900,000,000 shares authorized, 149,436,681 and 148,661,247 shares issued and outstanding at February 28, 2022 and August 31, 2021 respectively 14,715 14,475
Additional paid-in capital 17,819,072 17,063,363
Issuance of warrants 3,459,510 3,459,510
Other comprehensive loss (2,553,716) (1,905,715)
Accumulated deficit (19,387,609) (16,825,718)
Total stockholders' equity (deficit) (648,028) 1,805,915
Total liabilities and stockholders' equity $ 1,137,810 $ 3,078,961
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Feb. 28, 2022
Aug. 31, 2021
Statement of Financial Position [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized 100,000,000 100,000,000
Preferred Stock, Shares Outstanding 0 0
Preferred Stock, Shares Issued 0 0
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 900,000,000 900,000,000
Common Stock, Shares, Outstanding 149,436,681 148,661,247
Common Stock, Shares, Issued 149,436,681 148,661,247
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Feb. 28, 2022
Feb. 28, 2021
Feb. 28, 2022
Feb. 28, 2021
Operating expenses:        
Research and development expense $ 330,576 $ 315,958 $ 770,620 $ 749,688
General and administrative expenses 399,685 351,911 1,069,990 577,913
Total operating expenses 730,261 667,869 1,840,610 1,327,601
Loss from operations (730,261) (667,869) (1,840,610) (1,327,601)
Other income (loss)        
Capital gain 0 195,968 0 195,968
Financial Loss, net. (508,610) (62,854) (721,280) (57,889)
Net (loss) (1,238,871) (534,755) (2,561,891) (1,189,522)
Profit (loss) from available for sale assets (366,790) 2,622,133 (648,001) 2,735,220
Total comprehensive income (loss) $ (1,605,661) $ 2,087,378 $ (3,209,892) $ 1,545,698
Net loss per share - basic and diluted: $ (0.008) $ 0.004 $ (0.02) $ 0.01
Weighted average number of shares outstanding - Basic and Diluted 147,142,263 135,237,584 146,304,758 135,235,838
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Warrants [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Aug. 31, 2020 $ 13,508 $ 15,372,311 $ 2,784,387 $ (2,774,411) $ (13,631,271) $ 1,764,524
Shares, Outstanding, Beginning Balance at Aug. 31, 2020 135,080,441          
Other comprehensive income 2,735,220 2,735,220
Net loss (1,189,522) (1,189,522)
Issuance of common stock for services, net. $ 16 32,984 33,000
Stock Issued During Period, Shares, Issued for Services 157,143          
Issuance of warrants 439,330 439,330
Ending balance, value at Feb. 28, 2021 $ 13,524 15,405,295 3,223,717 (39,191) (14,820,793) 3,782,552
Shares, Outstanding, Ending Balance at Feb. 28, 2021 135,237,584          
Beginning balance, value at Nov. 30, 2020 $ 13,524 15,405,295 2,784,387 (2,661,324) (14,286,038) 1,255,844
Shares, Outstanding, Beginning Balance at Nov. 30, 2020 135,237,584          
Other comprehensive income 2,622,133 2,622,133
Net loss (534,755) (534,755)
Issuance of warrants 439,330 439,330
Ending balance, value at Feb. 28, 2021 $ 13,524 15,405,295 3,223,717 (39,191) (14,820,793) 3,782,552
Shares, Outstanding, Ending Balance at Feb. 28, 2021 135,237,584          
Beginning balance, value at Aug. 31, 2021 $ 14,475 17,063,363 3,459,510 (1,905,715) (16,825,718) 1,805,915
Shares, Outstanding, Beginning Balance at Aug. 31, 2021 144,747,584          
Share based payment 530,662 530,662
Exercise of CLA to shares $ 240 225,047 225,287
Stock Issued During Period, Shares, Conversion of Convertible Securities 2,403,294          
Other comprehensive income (648,001) (648,001)
Net loss (2,561,891) (2,561,891)
Ending balance, value at Feb. 28, 2022 $ 14,715 17,819,072 3,459,510 (2,553,716) (19,387,609) (648,028)
Shares, Outstanding, Ending Balance at Feb. 28, 2022 147,150,878          
Beginning balance, value at Nov. 30, 2021 $ 14,637 17,664,225 3,459,510 (2,186,926) (18,148,738) 802,708
Shares, Outstanding, Beginning Balance at Nov. 30, 2021 156,375,444          
Share based payment 104,925 104,925
Exercise of CLA to shares $ 78 49,922 50,000
Stock Issued During Period, Shares, Conversion of Convertible Securities 778,434          
Other comprehensive income (366,790) (366,790)
Net loss (1,238,871) (1,238,871)
Ending balance, value at Feb. 28, 2022 $ 14,715 $ 17,819,072 $ 3,459,510 $ (2,553,716) $ (19,387,609) $ (648,028)
Shares, Outstanding, Ending Balance at Feb. 28, 2022 147,150,878          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Feb. 28, 2022
Feb. 28, 2021
Cash flows from operating activities:    
Net (Loss) $ (2,561,891) $ (1,189,522)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Depreciation 102,411 114,007
Capital gain 0 (195,968)
Royalties receivables valuation 0 0
Stock issued for services 0 33,000
Profit from held for trading investments 0 0
Changes in operating assets and liabilities:    
Convertible loan valuation 678,391 0
Share based payment 530,662 0
Accounts Receivable and pre paid expenses 36,417 (18,294)
Accounts payable and accrued liabilities 59,688 (38,200)
Net cash used in operating activities (1,154,322) (1,294,977)
Cash flows from investing activities:    
Realization of Available for sale investment 0 645,968
Held for trading Investments 0 0
Acquisition of equipment (513) (943)
Net cash from (used) in investing activities (513) 645,025
Cash flows from financing activities:    
Proceeds from convertible loan agreement 0 1,206,750
Net cash provided by financing activities 1,206,750
Net increase (Decrease) in cash (1,154,835) 556,798
Cash and cash equivalents at beginning of the Period 1,386,472 777,611
Cash and cash equivalents at end of the Period $ 231,637 $ 1,334,409
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business, Presentation and Going Concern
 6 Months Ended
Feb. 28, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business, Presentation and Going Concern

Note 1– Nature of Business, Presentation and Going Concern

 

Organization

 

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.

 

On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.

 

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

 

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

 

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

 

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

 

On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.

 

On August 20th, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including in-vivo experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.

  

On October 18th, 2021, the Company filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.

 

On February 13th, 2022, the company established a Nomination and Governance Committee.

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited financial statements should be read in conjunction with our August 31, 2021 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 29th, 2021.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Going Concern

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $2,561,891 for the six months ended February 28, 2022, it has incurred cumulative losses since inception of $19,387,609. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

 

Research and Development Costs

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $770,620 and $749,688 for the six months ended February 28, 2022 and 2021, respectively.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
 6 Months Ended
Feb. 28, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

Note 2 – Related Party Transactions

 

During the six months ending February 28, 2022, the Company paid $244,920 in salaries, including socials benefits, to two directors, compared to $248,763 for the six months ending February 28, 2021.

 

During the six months ending February 28, 2022, the Company recorded a non cash expense of $530,662 in share based payment, to the company chairman, board members and advisor, compared to non for the six months ending February 28, 2021.

 

The Company had a balance outstanding on February 28, 2022 and at February 28, 2021 of $223,645, payable to Cannabics, Inc. The advance is due on demand and bears no interest.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Deficit)
 6 Months Ended
Feb. 28, 2022
Equity [Abstract]  
Stockholders’ Equity (Deficit)

Note 3 – Stockholders’ Equity (Deficit)

 

Authorized Shares

 

The Company is authorized to issue up to 900,000,000 shares of common stock, par value $0.0001 per share. There is also 100,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 – Commitments and Contingencies
 6 Months Ended
Feb. 28, 2022
Commitments and Contingencies Disclosure [Abstract]  
Note 4 – Commitments and Contingencies

Note 4 – Commitments and Contingencies

 

We lease the property of our corporate office in Tel Aviv, the monthly lease is $3,500, our current lease expires June 30th, 2022. The management intend to execute a lease agreement by that time for an additional year.

 

We lease the property of our laboratory in Rehovot, Israel, the monthly lease is $6,500 per month. Our current lease terminates at the end of February 2024, though we have a two additional one-year option, which management intends to execute prior to that time.

 

As security for its obligation under a property lease agreement, car lease and credit cards, the Company’s subsidiary provided a bank guarantee in the amount of $50,000.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Major Events During the six months ended on February 28, 2022
 6 Months Ended
Feb. 28, 2022
Major Events During Six Months Ended On February 28 2022  
Major Events During the six months ended on February 28, 2022

Note 5 – Major Events During the six months ended on February 28, 2022

 

On February 4th, 2022, the Company filed a Pre-14C Information Statement with the SEC.

 

On February 15th, 2022 the Company filed its Definitive 14-C Information Statement with the SEC.

 

On February 17th, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement with an institutional investor.

 

On February 18th, 2022, the Company filed an S-1 Registration Statement with the SEC.

 

During the six months ended February 28, 2022, the Company issued 2,403,294 shares of its common stock to an investor as a result of a convertible loan exercise in the sum of $225,228.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 6 Months Ended
Feb. 28, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 6 – Subsequent Events

 

On March 16th, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement as well as demand promissory note from an institutional investor in the principal amount of $280,000 with an original issue discount of $40,000.

 

The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum.

 

On March 28th, 2022, the Company filed an 8K with the SEC giving notice of its formal name change to “CNBX Pharmaceuticals Inc.”

 

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no such events that warrant disclosure or recognition in the financial statements.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business, Presentation and Going Concern (Policies)
 6 Months Ended
Feb. 28, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited financial statements should be read in conjunction with our August 31, 2021 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 29th, 2021.

 
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.

 
Going Concern

Going Concern

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $2,561,891 for the six months ended February 28, 2022, it has incurred cumulative losses since inception of $19,387,609. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

 
Research and Development Costs

Research and Development Costs

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $770,620 and $749,688 for the six months ended February 28, 2022 and 2021, respectively.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Business, Presentation and Going Concern (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Feb. 28, 2022
Feb. 28, 2021
Feb. 28, 2022
Feb. 28, 2021
Aug. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Stockholders' Equity, Reverse Stock Split     20-for-1 reverse split of our issued and outstanding common stock    
Net Income (Loss) Attributable to Parent $ 1,238,871 $ 534,755 $ 2,561,891 $ 1,189,522  
Retained Earnings (Accumulated Deficit) 19,387,609   19,387,609   $ 16,825,718
Research and Development Expense $ 330,576 $ 315,958 $ 770,620 $ 749,688  
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details Narrative) - USD ($)
 6 Months Ended
Feb. 28, 2022
Feb. 28, 2021
Related Party Transactions [Abstract]    
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold $ 244,920 $ 248,763
Share-based Payment Arrangement, Noncash Expense $ 530,662 0
Due to Related Parties, Current   $ 223,645
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Deficit) (Details Narrative) - $ / shares
Feb. 28, 2022
Aug. 31, 2021
Equity [Abstract]    
Common Stock, Shares Authorized 900,000,000 900,000,000
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized 100,000,000 100,000,000
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Major Events During the six months ended on February 28, 2022 (Details Narrative)
 6 Months Ended
Feb. 28, 2022
USD ($)
shares
Major Events During Six Months Ended On February 28 2022  
Debt Conversion, Converted Instrument, Shares Issued | shares 2,403,294
Debt Conversion, Converted Instrument, Amount | $ $ 225,228
XML 28 cnbx_i10q-022822_htm.xml IDEA: XBRL DOCUMENT 0001343009 2021-09-01 2022-02-28 0001343009 2022-04-12 0001343009 2022-02-28 0001343009 2021-08-31 0001343009 2021-12-01 2022-02-28 0001343009 2020-12-01 2021-02-28 0001343009 2020-09-01 2021-02-28 0001343009 us-gaap:CommonStockMember 2021-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001343009 CNBX:WarrantsMember 2021-08-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001343009 us-gaap:RetainedEarningsMember 2021-08-31 0001343009 us-gaap:CommonStockMember 2021-11-30 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001343009 CNBX:WarrantsMember 2021-11-30 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-30 0001343009 us-gaap:RetainedEarningsMember 2021-11-30 0001343009 2021-11-30 0001343009 us-gaap:CommonStockMember 2020-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-08-31 0001343009 CNBX:WarrantsMember 2020-08-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-31 0001343009 us-gaap:RetainedEarningsMember 2020-08-31 0001343009 2020-08-31 0001343009 us-gaap:CommonStockMember 2020-11-30 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001343009 CNBX:WarrantsMember 2020-11-30 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-11-30 0001343009 us-gaap:RetainedEarningsMember 2020-11-30 0001343009 2020-11-30 0001343009 us-gaap:CommonStockMember 2021-09-01 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2022-02-28 0001343009 CNBX:WarrantsMember 2021-09-01 2022-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-01 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2021-09-01 2022-02-28 0001343009 us-gaap:CommonStockMember 2021-12-01 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-02-28 0001343009 CNBX:WarrantsMember 2021-12-01 2022-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-01 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2021-12-01 2022-02-28 0001343009 us-gaap:CommonStockMember 2020-09-01 2021-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-09-01 2021-02-28 0001343009 CNBX:WarrantsMember 2020-09-01 2021-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-01 2021-02-28 0001343009 us-gaap:RetainedEarningsMember 2020-09-01 2021-02-28 0001343009 us-gaap:CommonStockMember 2020-12-01 2021-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2020-12-01 2021-02-28 0001343009 CNBX:WarrantsMember 2020-12-01 2021-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-01 2021-02-28 0001343009 us-gaap:RetainedEarningsMember 2020-12-01 2021-02-28 0001343009 us-gaap:CommonStockMember 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001343009 CNBX:WarrantsMember 2022-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2022-02-28 0001343009 us-gaap:CommonStockMember 2021-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001343009 CNBX:WarrantsMember 2021-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-02-28 0001343009 us-gaap:RetainedEarningsMember 2021-02-28 0001343009 2021-02-28 iso4217:USD shares iso4217:USD shares pure 0001343009 false --08-31 2022 Q2 10-Q true 2022-02-28 false 000-52403 CNBX PHARMACEUTICALS INC. NV 46-5644005 #3 Bethesda Metro Center Suite 700 Bethesda MD 20814 (877) 424-2429 Common Stock, $.0001 Par Value Yes Yes Non-accelerated Filer true false false 149436681 231637 1386472 167958 204375 399595 1590847 197217 845218 540998 642896 1137810 3078961 237193 177505 1325000 871896 223645 223645 1785838 1273046 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 900000000 900000000 149436681 149436681 148661247 148661247 14715 14475 17819072 17063363 3459510 3459510 -2553716 -1905715 -19387609 -16825718 -648028 1805915 1137810 3078961 330576 315958 770620 749688 399685 351911 1069990 577913 730261 667869 1840610 1327601 -730261 -667869 -1840610 -1327601 0 195968 0 195968 508610 62854 721280 57889 -1238871 -534755 -2561891 -1189522 -366790 2622133 -648001 2735220 -1605661 2087378 -3209892 1545698 -0.008 0.004 -0.02 0.01 147142263 135237584 146304758 135235838 144747584 14475 17063363 3459510 -1905715 -16825718 1805915 530662 530662 2403294 240 225047 225287 -648001 -648001 -2561891 -2561891 147150878 14715 17819072 3459510 -2553716 -19387609 -648028 156375444 14637 17664225 3459510 -2186926 -18148738 802708 104925 104925 778434 78 49922 50000 -366790 -366790 -1238871 -1238871 147150878 14715 17819072 3459510 -2553716 -19387609 -648028 135080441 13508 15372311 2784387 -2774411 -13631271 1764524 157143 16 32984 33000 439330 439330 2735220 2735220 -1189522 -1189522 135237584 13524 15405295 3223717 -39191 -14820793 3782552 135237584 13524 15405295 2784387 -2661324 -14286038 1255844 439330 439330 2622133 2622133 -534755 -534755 135237584 13524 15405295 3223717 -39191 -14820793 3782552 -2561891 -1189522 102411 114007 -0 195968 -0 -0 0 33000 -0 -0 678391 0 530662 0 -36417 18294 59688 -38200 -1154322 -1294977 0 645968 0 0 513 943 -513 645025 0 1206750 1206750 -1154835 556798 1386472 777611 231637 1334409 <p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zFpu9QKgcExj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1– <span id="xdx_823_z8eQCGQ705F1">Nature of Business, Presentation and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20210901__20220228_zikeKg3VtgN5">20-for-1 reverse split of our issued and outstanding common stock</span>. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2014, FINRA granted final approval of Change of Name &amp; Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 20<sup>th</sup>, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including <i>in-vivo</i> experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18<sup>th</sup>, 2021, the Company filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13<sup>th</sup>, 2022, the company established a Nomination and Governance Committee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zvSBGT2KpNpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited financial statements should be read in conjunction with our August 31, 2021 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 29<sup>th</sup>, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_z22hSjrZQttg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--GoingConcernPolicyTextBlock_zo9qK4PBwkP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20210901__20220228_zGz45woDymsg">2,561,891</span> for the six months ended February 28, 2022, it has incurred cumulative losses since inception of $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220228_zErThhIQUzGd">19,387,609</span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zViIRH4FwZl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Costs</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210901__20220228_zllSlFPilI63">770,620</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200901__20210228_zinp3fcJBbVi">749,688</span> for the six months ended February 28, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 20-for-1 reverse split of our issued and outstanding common stock <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zvSBGT2KpNpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited financial statements should be read in conjunction with our August 31, 2021 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 29<sup>th</sup>, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_z22hSjrZQttg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--GoingConcernPolicyTextBlock_zo9qK4PBwkP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20210901__20220228_zGz45woDymsg">2,561,891</span> for the six months ended February 28, 2022, it has incurred cumulative losses since inception of $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220228_zErThhIQUzGd">19,387,609</span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> -2561891 -19387609 <p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zViIRH4FwZl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Costs</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210901__20220228_zllSlFPilI63">770,620</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200901__20210228_zinp3fcJBbVi">749,688</span> for the six months ended February 28, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 770620 749688 <p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOJIEhHH5Qvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 – <span id="xdx_824_zBgZ4fObIvw8">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ending February 28, 2022, the Company paid $<span id="xdx_90F_eus-gaap--SalariesAndWages_pp0p0_c20210901__20220228_zvZwdQIREXZ7">244,920</span> in salaries, including socials benefits, to two directors, compared to $<span id="xdx_90F_eus-gaap--SalariesAndWages_pp0p0_c20200901__20210228_zjzquYuAEiDd">248,763</span> for the six months ending February 28, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ending February 28, 2022, the Company recorded a non cash expense of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210901__20220228_z0vCD6XYVikc">530,662</span> in share based payment, to the company chairman, board members and advisor, compared to <span id="xdx_907_eus-gaap--ShareBasedCompensation_do_c20200901__20210228_zQKWhfxCA9h9">no</span>n for the six months ending February 28, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had a balance outstanding on February 28, 2022 and at February 28, 2021 of $<span id="xdx_903_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20210228_zgdtbWnqOvjk">223,645</span>, payable to Cannabics, Inc. The advance is due on demand and bears no interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> 244920 248763 530662 0 223645 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrTh5Y01Ype6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 – <span id="xdx_827_zEXUfgjqFZrh">Stockholders’ Equity (Deficit)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized Shares</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue up to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20220228_zCy01ELzfe7k">900,000,000</span> shares of common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220228_zujLEUa7XDwg">0.0001</span> per share. There is also <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20220228_zpU9Nm5Wyq76">100,000,000</span> shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 900000000 0.0001 100000000 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zoXr3HLs2Cx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4 – Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We lease the property of our corporate office in Tel Aviv, the monthly lease is $3,500, our current lease expires June 30th, 2022. The management intend to execute a lease agreement by that time for an additional year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We lease the property of our laboratory in Rehovot, Israel, the monthly lease is $6,500 per month. Our current lease terminates at the end of February 2024, though we have a two additional one-year option, which management intends to execute prior to that time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As security for its obligation under a property lease agreement, car lease and credit cards, the Company’s subsidiary provided a bank guarantee in the amount of $50,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_80D_ecustom--MajorEventsTextBlock_zifFcTa53iK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 – <span id="xdx_82E_z698VWXttWN9">Major Events During the six months ended on February 28, 2022</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 4<sup>th</sup>, 2022, the Company filed a Pre-14C Information Statement with the SEC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15<sup>th</sup>, 2022 the Company filed its Definitive 14-C Information Statement with the SEC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17<sup>th</sup>, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement with an institutional investor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18<sup>th</sup>, 2022, the Company filed an S-1 Registration Statement with the SEC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended February 28, 2022, the Company issued <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210901__20220228_zvduqMAFOD6k">2,403,294</span> shares of its common stock to an investor as a result of a convertible loan exercise in the sum of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210901__20220228_zLrKQlR1rbyg">225,228</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> 2403294 225228 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z4KU5St9LDt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 – <span id="xdx_825_zFJguAPaI4X7">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16<sup>th</sup>, 2022, the Company filed an 8K with the SEC relating to a Forbearance Agreement as well as demand promissory note from an institutional investor in the principal amount of $280,000 with an original issue discount of $40,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 28<sup>th</sup>, 2022, the Company filed an 8K with the SEC giving notice of its formal name change to “CNBX Pharmaceuticals Inc.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no such events that warrant disclosure or recognition in the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> EXCEL 29 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "A/C%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " H3XQ4-)I?*N\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:15!Z'+BV-/"H(#Q;>0W+9@TX;DI-VWMXU;A^@'\#%W__SN M=W"-"=+T$9]C'S"2PW0S^K9+TH0U.Q(%"9#,$;U.Y93HIN:^CU[3](P'"-I\ MZ -"Q?D]>"1M-6F8@458B$PUUD@345,?SWAK%GSXC&V&60/8HL>.$HA2 %/S MQ' :VP:N@!E&&'WZ+J!=B+GZ)S9W@)V38W)+:AB&MW!= M(MT9G'XE)^D4<,TNDU_KA\UNRU3%JZK@MX6H=J*6=RO)5^^SZP^_J[#OK=N[ M?VQ\$50-_+H+]0502P,$% @ *$^,5)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" H3XQ4$9FOB1$% #B% & 'AL+W=O_0D-[L3L3P);-1W8(,\1)=IDF+ ELVFVG%\(6X%G;HK(< MDG_?(V%LPIAC>I/XZ[P\.L=ZCZS!5LB?Z9IS15[C*$FO&FNE-I_;[=1?\YBE M+;'A"=Q9"ADS!:=RU4XWDK/ !,51FUI6MQVS,&D,!^;:5 X'(E-1F/"I)&D6 MQTR^7?-(;*\:=F-_X2E9*&(B&2+Z\: M(_NSYY@ \\1SR+?IP3'10UD(\5.?C(.KAJ6)>,1]I248_'OA'H\BK00<_^:B MC>(W=>#A\5[]S@P>!K-@*?=$]$<8J/55H]\@ 5^R+%)/8ON5YP/J:#U?1*GY M2[:[9UVW0?PL52+.@X$@#I/=?_::)^(@ 9:'4#S 'H48)_Z!2% BBV1^FE0TP%N"'%JZ(D7+DF3I&LF>3IH*]#4 M=]I^'G^]BZE7$\W+::CPA%IZ#HH#(C0 @,QEW$5E48>/R212E'.+H%1_>\;#QF3"HN MHS?RQ#="JBHD7$K)#"/J%42],^LC&=B5<9O32+A679;Z!5/_/*8IEZ$(]&PC M,-\K7Q]<:3^_?OGPH6:*7!9LE^>QW86ISZ(]XAUYG9#SQ6AAF:>%E5#4,33"5_([?ZL$Q:4@?[;C.I9U MB9&5%F_C'IV3S=DK&0> %RY#GQD_0RJ,2[K=9J?KNI;5P0A+\[=QR\X)QXDO M)#BL@;L@,P7S@0A)/)%!4B&W(JBN.ZX^><8@RWY@XR:>0XZ" )9(Z<7^@-S# M<^1;4DV&2_[JD&NNUCP-&'G@2@KS^AQ7Y#UOV2MLW.)1WOE65/+BDK,LA(KT M+ L#+!N&C7O\,:"GSZ#<<[%-*N%PN7TFL=5GV3@H[O7';,6[.)7B)4S\RFK7 M:#[<8&AE]Z"XW1^C346JP'#^"CV#XLYO2CB"#\G3*+C MQWZO]PE#*=L&Q=W^7IA5R%HD6">K$7&IVZ0NQ7R8EAV"XK8^#Q5T5;&$#Y./ MJT]DQOU,0KXJL7 E3\0QV/=,"?_G!?FMI1L&F<(JXIE%Z.*7EDV#GM4T]DN5 MW7& VYG*EWZXOH*#6X![QAB75N<,%ZSZUG+(%.&>U@-F:0ZX0 MH!J96J#2^)VSC/_]Y)^9'1OR+5/0!9( MTNWWX M;G@YQ&H?["+IJIC-M93X>@VVVU JKA8;>".S;=4N']_M_CTP7=241'P)H5:K M![\O=QMJNQ,E-F9/:B&4$K$Y7',6<*D?@/M+(=3^1/] L:TY_ ]02P,$% M @ *$^,5/Z19%0'!0 A1$ !@ !X;"]W;W)KN'84&S;I\9B8Z)2J)+4G:R7[\C M[N:ZY=/ MHE+[FQF9O3[X)I\VUCU8K)9;_B0>A/V^O=53JAYM\+6]FV"$2E2BL,\'A9R?N1%4Y2X#CY]'HK%O3 M*?;'K]:_>.?!F4=NQ)VJ_I6EW=S,LADJQ9JWE?VF]G^(HT.QLU>HROAOM#_* MXADJ6F-5?50&!+5L#K_\^1B(G@*)1A3H48&^58$=%9AW](#,N_696[Y::K5' MVDF#-3?PL?':X(ULW#8^6 UO)>C9U9UJC*IDR:THT2=>\:80Z,&9,^C]]X:W MI80W'] 5^O[P&;U_]V&YL+"L4UX4QR4^'9:@(TM\$8_7B&9S1#&E ?6[:?7; M]ND:,>+5R;GZ ISM/*:=Q]3;8V,>MUJ+QB)N##CY<<(BZRPR;S$:L\C-!O&F M1(4;B)^MW/$*EC"A6!U,)=Z4R['=BC*2L'2YV/5C,A0C+$NBE'9R9U"C#FHT M"?5>BRV7)1+/4 >,,!ZVLANA(2<+ < ?*Q'$?; ;]P$E:1YG%[B'8A1'+(W# ML.,.=CP)^V]E>07IT-^Y$,AXL#K+\SB/+T .Q4B+(4THNS\)0+(MB2K(PVK1#FTZB_1W.Z=8A MFZ-&!.&E@W7C".?YY98/Q9*(9GD2AI=U\+(W;/GX5F?#V!&69@1?H!O*,9P" M.A*&EW?P\C=5D4KR1UE)*\5D*2'X5(_Q]"$J"M5"[4!;_N+/DLM07A2ZA0+= M6RU8A_$P^UA*2JT M+^@]M%6RD/;#9(:%LQ1P3C.3Y\ MD-EP[8BNM1NEY7^BA'JG7I]*8UQ>>19LK;$PD,U3,+A#TA@5.U35TNZ.>YM.>DBB?1RR9)QGQ3I(HFR<)F=,HG0X!XA9!XZ9;Z.V[YLT+ M03\&;6G7D4$2F:WPS7@5SJ$ RT4I&:102"P::QS(B>7(-,W=EM#!PH4!TLAU M/E>R@39M*R&M@F"'9 8I1'+<:[R.>$.2.&$L82.03\Q'IJGO*^R([\/5&NVY MUGRDE20!;HN@VQEPX!L$SZ&>6)#DDU#_\JUCH6JX0V[,D% D&0XSD<#W;ME39/L 7J/ ML7SQ"+D2=( .[S_!]BX@&.[O%KT[LON#XD^NGV1C4"76H(FO4XB!/MSY#Q.K MMO[:_*@L7,+]<",X '<"\'ZME'V=N)MX]\_+ZG]02P,$% @ *$^,5*^> MVBE3KR 02H (DR5>O%-%34[F+:A4D.Q*IC,]LIW7[]CITT@S9\%"[ M'^=]_9S#B9SA1JHGG0$8\I)SH4=>9LSZVO=UDD%.=4NN0>#.4JJ<&IRJE:_7 M"FCJ1#GWHR"(_9PRX8V';FVFQD-9&,X$S!3119Y3]><&N-R,O-![7;AGJ\S8 M!7\\7-,5S,$\K&<*9W[MDK(63 MG=RE(R^P1, A,=:"XL\S3(%SZX0[GY"E5"7>N72*[=-]F4L?' (TFAC27,RH F$R,"RA_))\)I^(3W2& MJWKH&R2Q?GY2G7I3GAKM.?46%BT2]:](%$11@WQZ6#XI5BW2#IT\W)7[F']= MA*@N0N3\VGO\Y@;3Q]XT1"[)+1-8!$8YF4G-7*_]G"RT4=AQOPX""+6Y3;4O_GO.WC^GS.&@% M08"5>-ZNX=&P'?Q.C=_Y&+[#U&12F$PJ]A?2)N32L[O%$@;5YPWU*9$[X-T: MO'L6^/?":$-%RL2JB;S[CN[IW6PT?#=MC[-7O_ ^PG-7#_7?T&>QKXE,@=ZD%-/?@P]=6Q M]AV\?YPZ@TX[COMO2]T4V8_C,.KTFKG#X/\=$YQ!OK^=*[M3J!M#F[']K5O2 MOJ)\HVK%A"86M7TZ,7+N+ONGJNUDK9=%[D9?F=K*V M=G,3!&:Q5H4TUWJC2OAEJ:M"6CBM5H'95$JF=5"1!Q1C'A0R*R>S:7WML9I- M]=;F6:D>*V2V12&K?^Y4KM]N)V2RO_"4K=;670AFTXU4VMT_Z M[1?5"JHWN-"YJ3_16XO%$[38&JN+-AAV4&1E\RW?6R.. H#''T#; -H/",\$ ML#: ?72%L T(/[I"U ;4TH-&>VWU^'0U^9:5+E&=; MP:\9Q-G97)=&YUDJK4K1LX4OR )KD%ZB/S:JDNYN&B3+%,UU :FX=CFR4^@W M;0RZ>"GE-LT@]!)=H9?G>W3QT^4TL+ OQQXLVCW<-7N@9_; T%==VK5!#V6J M4D_\_7@\'XD/P(_.%+HWY8Z.$GY1K]>(BD^(8DH]^YE_/)SXY/R_U1_^\^HG M9K N0UC-Q\[PM6E0KI!ZA_)DE+D980T[UK!F#<^P/BFC9+58UZF5JAU4K(W+ MO/TBOBQJ&'G-Z K@;L88CF(^#7;'-\<#(U$2B5/8_1 6QYA3? I[\,#"A(L# MVXG\J),?C;#W80,TQY3]!\".,\ M%CSIZ1["B @Q)WW='ARC,CPNO2N:QTL1%3BEZR4Y2(#D2YW/J%2V6OO M:Q8/[UR$Q> .SWU 3D44]B3[<#$E5/25>U>.A4C.2#]J3\BH]-^A5_:E2BN8 M>%*5,B'B_D/B0T8LC*.H+]D#I!$G(B%]S;[% 1>YM[97-3VHIJ.J'RN]S/;" MFUHA=S++Y6NN$$P'R$@XD,8HZRT=+?W)UA@4A7YIGWN E%-*&.O;XF'DHP#+XS%21LZ4DQ:)]C@_7U%.([XH(QZD!2+F,7].N"C M9!0G(J%]+X9($H413\Y5A$/W1,;;)_=8.,T(WB#(K&6EH &'@2E;- U5EF^A M*[_Q.M(PB^/MXVN,1=^/(<[!!B6B@24]NH$50QB@SKQ0R*&-(N-]U+=Z$(31 M1>[@5;I2J-P6KV )C"^U*S#(;*VQX(EK,:[076?1?6.1UR%/8Q3&)*24L[Y) M'B@D.XLC,3#*Q\H9AAHD^F:=88T$ZV=.<#3Z%:I:U3.W@:=D6]JFQ^^N=G/] MYWJ:[5V_(S=SXKE^[_X'J$?- WWS)\)76:TR& YSM82E\'4,^ZV:N;PYL7I3 M#YZOVL(86Q^NE4Q5Y0#P^U)KNS]Q"W3_CLS^!5!+ P04 " H3XQ47<"F MH 0( !-,@ & 'AL+W=OOUPN@_$WL2H&%Q8)^V_OP538W:'-41[ M7Q(3SSP[S RSSP/DZB7+OQ8;S@7ZODW2XGJT$6+W;C(I5AN^C8K+;,=3^Y'$*;_+4;'?;J/\ MQWN>9"_7(SSZ^8=/\=-&E'^8W%SMHB=^S\7GW5TNCR9'E'6\Y6D19RG*^>/U MZ!:_6U*O=*@L_H[Y2W'R&96G\I!E7\N##^OKD5-&Q!.^$B5$)'\]\RE/DA)) MQO&M!AT=URP=3S__1%]4)R]/YB$J^#1+OL1KL;D>!2.TYH_1/A&?LI??>'U" M58"K+"FJG^BEMG5&:+4O1+:MG64$VS@]_(Z^UXDX<2"DPX'4#D1QH'Z' ZT= MJ.* @PX'MW9PU158AX-7.WCJ.70Y^+6#KX9$.QQ8[<"J8AVR6Y5F%HGHYBK/ M7E!>6DNT\D-5W\I;5B1.RU:\%[G\-I9^XF::I466Q.M(\#6Z%_*7[#-1H.Q1 M'F6KKYLL6?.\^!7-O^UC\0.]F?''>!6+M^C-YS3:KV/I]Q:-T>?[&7KSR]NK MB9!!E="351W ^T, I#. [5:V9+48^NCA)T%\7K M<9RB:;2+A3PV@,[,H%^B/(_*;!@@YF?B^CC]@&Z%R..'O8@>$HY$)B/,99)- MJ LSZB1JG3\8(EV:LOS*9I+;;1#;1L9/(L9-(A>-VX+SG3W%: M!B-'0Q*E*WZ!GJ-DSU$DT.W^Z1)1?(&(0QRH1P[0?@5=3L_G&TP])[B:/)^V M &#E448HQFW#F6Y(6.#2@+7MYKK=F##FNBK@ C#$U*>8,,5R"<3(?-;Y 3*]>'A3PUUXX\;3A&]QBC M:XSQH]CP'*VRK=P4-^5N]PJA'REJT6LK2>LOSZ[6*Z1V+Z1F+^:>D04E6%%#IC)X#2F<) M9V8)9VX)9^%I)1EC'(2R*,JPZ&'8*IY_+)YO+-Z'HMA7\T!NXZO#!EM4&ZSD MKJB,/%Z5PR3EXA*JKZ_/,%\9Q;X6.25AX"ISV!CE@,)8PEE8PED"9T\=I^.* M8\>B,?.(KRI4EDYN[+-]7L[U.Y['V?H"_1S_];=E&>_K,D(%9/J(]QAV*1Q@ M< PPZ-U5+S4U@E8WH@P8#Y9P9H&6#9>&LF *&;"TW,(2SO)LV*TBAL .&RAI"'(THE_PT!%K/=3P2>LILT TI(91AE:/I=F,: MXE!E:( 9=@/BL) J0Q=8F 7$\SIF+G8:*>4,YVAUOD\(VME$U\LH#$WFQ@LZ M6"0^D7OXU2S]S^Q9,D>GFSG6V.=:H#;KT0. )4S4 <,Q\7U,U<47D"5V2> [ M5)$32RA.V0>!VY7E1@IALQ;JS];/YYP,;H9&4V"SJ!A&V,U@ ^:Z+:"9+: Y MUC41\0G!E*K=96G%98\5VT5M1!@VJS 3<3>[#BFA+=5E"VAN"VB!=4$U]JC+ M/$\='^<-VR5LI!0'CJA M>H"V1KOH1_G !;PG;D09,-V)KB<\ZOB^>5X_:RYI61R(NG]S=\Y5T$7%'<76A M)HM+2=@U+QJ91FS*-#/8D+%A2Z;9 IH3732-?3=P'.UQG2V9UF/%=E$;F49> M+]/,KD-*:$NFV0*:VP):$$!]$<_'@4I2EWTLVT5LA!HQ"[5>W)Z )?8 3J?1 MJBG150EF@:1@3-N\=4N8TP&&,AV>5 &^>A5!CZ="&C#?"=4< Z;E=4*"CA0W M\HF8Y=,KV#V<<$ EE0EW M858Z- B%F!]+VI"C+-&KO="3YE:B< ZH3YOBLW M1K43=,N.3M -QP0'?DBT3@ L<2"5'M-NJ@*FL@V8TY7D1D(1LX1ZW3U5..6 M O%DRCVWZ]8O:30(Z:%!>I![(\J0$0\(%<<-]:ZPM.#<%M#"%M#R? K:K]PT M0HV:A=H@HRQ U#];6 F3FL ;6R!;2P!;0$,N YG8_.::/# MJ%F'_9_,GNIRA)5/J;I>Z6KD"#7+D6'$W@PV8&38 IK9 II373N-J>^S4'UI MRM:*RQXKMHMZ\J*>6:V9B+W9=4@);6DS6T!S6T +"D@N3&@0:*]:]K%L%[%1 M9]2LSEY/[&O@<\0>,H.)/6 )TSG L(/80Y8=Q!XR-1%[VF@G:M9.MH@]!212 M![&?G+PG7_ZCQ1]1+NEC@1+^*'V=2R9!\L/_+AP.1+:K7IU_R(3(MM7'#8_6 M/"\-Y/>/629^'I1OXQ__@^3F/U!+ P04 " H3XQ4=@Q_P&8% !/% M& 'AL+W=OO@KY M76T8T^CGMJS4W62C]>YF.E7YAFVI^BAVK(+_K(3<4@V/O+]XYNN--B^F\]L= M7;,7IK_MGB0\35LK!=^R2G%1(V8&5I+ &.'XW12;NG43Q>OUO_9)T'9Y94L84H_^&% MWMQ-L@DJV(KN2_TL7C^SQJ'8V,M%J>Q?]-K(!A.4[Y46VT89$&QY5?_2GTT@ MCA3 CEN!- JDKQ"-*(2-0F@=K9%9MQZIIO-;*5Z1--)@S2QL;*PV>,,KD\87 M+>&_'/3T?"$J)4I>4,T*]*+A!W*D%1(KM*!J@SY!GA6Z^E;1?<%!Y@.Z1M]> M'M'5;Q]NIQH &#/3O-GLH=Z,C&R6H"^BTAN%_J@*5ISJ3P%XBYZ\HW\@7H.? MV/(C(MGOB 2$./ L+E?''CAA&\S0V@O'@FDBMK(16TFQ1=!LDFI>K>MJY9HS M=>/9)VKWB>P^T<@^7Z&]K_X22CES4.LF5M=T\6%^3>($9S-P\7 <'(<@!K'8 MA/+@@!>W\&)O&.Z+?Z%PZSJ2[,>>2Z@M+6"=BRKG)4,5.% "?O/6K',3N+T" M,5[]KJ'$-9[%LR1S \M:8)D7V+-XHZ5)@4D?XP>Z+&%] MH.5^-)#96:P^B1.4LQ;ES(OR18O\.^)*[:&&@-R08O+ D5/(1_2 _2-M M0ZLU)/RT+Y5BT-NT*E#)Z9*79WL4DVY#XF\$ 7&0FD.9P8B@E;_4&F/'+B=I M%@Y&G4-N+#3=L,>AO^8V5#)[ABC0CKZ9S#DAAH.MXS!($M*'.)0;@]CQ!/83 MQ7V>B[T9P\]M[]JLP2 $R+Q [">.,S*(1\!V+ MX/@R\!#<%CG-40WV<\W72TC-"7Q( M+T#*<1220;VX)"'LLW2$BG#'13C]I7-,/9HN9V3=^QQ.8(J_A]B$(T(YJ"+ZL9VS-79G.^6!: MQU5]3O#X(O!#*2B'@,0C\#OB(N27FF;%*PJGW8N;AG3$0_S$ \>(G+&BV2?O M$R9=2\9&,^QCF29"0Q%,@B2-QTJQHR-R_KO%9G@GQ8'#)R!:OCGCY$3NM6VN M.V[4CN;L;@+L9HY_;#)'SF_"(6'Y_>L8B_@9R_C'JUPR.!.@JT=6KVP1&[>= M7CD8R,S[+(S[:7%06IRDLY$Y1CJN(GZNLH5KN-6FQLP'.'+9CS>JT9*M>569 M[,#LT!N&GICDHG"ZXO@R"K,D2OO,Y1!,TS0Y^M(Z]:3C+7+N(\KC"8/WYWU( M!]_$),1)V#_T..1P&$91,.OY,#VZFMDRN;8W5@K9DTU]S]&^;6_%[NU=4._] M [Y9U'=;G9GZJNT+E9 CA4JV I/!QQ0"*^O;J_I!BYV] %H*K<76+C>,%DP: M ?C_2@C]_F V:.\0Y_\#4$L#!!0 ( "A/C%3COQ+\^@D -,7 8 M>&PO=V]R:W-H965T&ULM5A=<]NX%7WGK\"HZ4XR0\N2[/@C ML3TC:Y.LVXWCM>)N9SI]@$A(1 ("7 "4HOWU/1<@*#,WMN0>CW9QZ"HK>!X. ME>IP-!B<')9[DH/"T< M7EU4?"&FPC]4=Q9/AYV47)9".VDTLV)^V1L/WUP?T_ZPX1]2K-S6;T:6S(SY M2@\W^65O0("$$IDG"1S_+<5$*$6" ..W1F:O4TD'MW^WTM\'VV'+C#LQ,>I7 MF?OBLG?68[F8\UKY>[/Z233VO"9YF5$N_&6K9N^@Q[+:>5,VAX&@E#K^S[\U M?O@S!T;-@5' '14%E#]RSZ\NK%DQ2[LAC7X$4\-I@).:@C+U%F\ESOFK6^YK M*YB9L^O:X9US*;NSP@GM>72;SMD'(_6"38S.A-47AQYZZ?1AUNBXCCI&3^@X M81^-]H5C[W0N\MWSA\#;@1ZUH*]'SPI\+V9]-CI+V6@P&CTC[ZASPE&0=_2$ MO$]VP;7\/1B]8_\:SYRWR+)_/X/H MN$-T'! =_U_#\JP.*O_JUGC!AC_\Y6PT'+YE_ST,MNU+ M-KF]_B>[*SC*)Q.UEQE7CMWHK,]>^D(P4C,:O)V8LN)Z'9Z&;U^ER8H[)G5F M;&4L_)OC@='^X&U"A!%NZ5P-:70&;.P\?E"@=B#" M!^/*2L5&P7E#.(_)@B7O1O*[Y;\$-YG;YU.^9BF[>2(KMK.2+,7@S/SX)([*IB_=&1 MU\._!N,^\C4;#?<%,(8,!02"HEI(DZ5$ % %R/FFJMSCJH(#GB[!ERU@4F8IB$%SPMUJ#M\Y;'[R_N;T?LX5%/"%^#KY6C%>5-2BH!"HF M07$PFACB!UY6;]EGF7V%6Z;K_A\,QG_/&4WMY-^&M,TL!*&E:@LV2AK*P?GFZ+ILRF7>8>;$2TB M^CFTDU5U]1S#=L&92T4PH6%L\5[%;/P84R! :BU*]EC488[) <8$-7H$DX0T M?-PFH//1_7WVT!&PXJNM(GJ4:$^"#QT@9&D>$5#(I6XJ\UXL)+5:E-\&WV:1 MS019$5*[MDNYI">J&+^.V=?:SBGIRDJ)X,T >=H,B^>C<7]X-D@:Y(WQ]V(I MJ;[)D-H+D![R"!W$TOZ401Z2B6:<- #&LZNS(F6Y@=.U\4CA0()!9A?61D>H M]L(HP @>$[ L.C'9L@UD\'1M$IO7"VIT^^GUZ,0QA-\YRH23+-GD1C64KX%7K [/2U+;JF9.Y1&[T&KIK*4C9U*%M$;6 M6?E,25>00HHI9PNAA2?6WB(8I%<#C,&,A38..["*$3M,_CFE>E&7< F.&[ I M\W4)S)TPLLU5(I-@09;%SJ"-S-U.; : "E,.D)J&UC]EWH0!YHQ>8 'SK:VI MQH9'M'+-G0PIL3-Z4293#PP&4XK7FM>Y;/DNSJ>NFT^3@B\%2D-HXA#,%G&L M>MQ%Z;F.W:5A=2(,,M!RA)K>T\S4C60/.F@,I>VZ%'KH3Y$#X_%=U_XIM"A@ M$$V9[(''JL=3Y1YL= W#\'3P2Y^-PRN@5.L0^#5J+%08(*L:Z0:PW7BAX]VU ME3PWQF,K\JTIQZA,ZQJ(]KFNC^H*DDP%@HQ7 "0![JQA! BOGG=^&)@X:0$L MGG]!&L3UEWB!X)*_$Z-58%5-:!4*)JNMI4# #T@'Y5ZA<:"Y.AYSM7$9FW-I M<9)0;'17&'4ZB[$1E]200KC-QPJ.R9IQ5[ Y;N8N4F.S,]G=V6BB&0WD16YN M@4A%LUCH2+A)%(31V3;Y_IY2 M1VW[4B@!2O8I12NP&/DU>?!HY&)2$CG5QHHBQJ,"$L!PVM M@/84U5],%NI CF^"@F(U?M?92HWSGA&WNHZ^*%FT>CZ+62H&P5 ]E07*S'Y/OY MM,]^+9 *.XXMXM6UMO&J@[[ <.L(_G_!1NGKDV%Z=CZD2?7H[#0]&9Q'GP2= MZ\=10OV0.5+C#ACZ;; [:>U&4\A%10,'XA:F06IV&_PX'HG;BW!#A!B7[@C% M;\LQT@#R4D1.8LT=-]UNU)&1:50*6TA-ZX0$KD:<;PUYMK:!K6DZ1N$O0 GD M0NYWK ICP8R&LXQ(9%ZKQM/ @Y.$ \[BKC3<>;TEV,V]Q!=AX*(J3%Z=&@GG@_0$ MP\CI\7EZX]:$U7$_H[ M2BH[BTKGZLLXMGF)%;?GND9%)VMM*N[(-)O8U@9Y$4"5C%F2C..*"Q7-I\&W M-/.I;IP4"I<&;%-5W.P7*/5V%@VC@^->;$KG'?%\6O,-/J#[6"\-67'/4H@* ME15:@<'U++H:7BXR'Q\"/@GF#"JAVI7ONGLX DR29P"L ["0=RL4LKSACL^G1F_! M^&AB\YM0:D!3'1\.5Y>&^[#1VQ.^CXKSC M6K1<[!FN,=QIY4H+;U6!Q:_XF/+JDV.'Y!;L).$MKLZ!30; $L9.\*5]L6G@ M2_^Z6/ARM;+.D/7UA$[6ZV1!)_LOEWJ:ZX-V" Q>O9BPX? -G"CAIC%";<"5 M"%;LH&K? E7AO725IJ&NZZ]S<.8#KW55<[6'FHL"7@++LL%KEM Z&5R,TW^B M-)AK0_\!<%#4?CFW)>".AHE%T&L2&Z7)8#QF= J/1[B2>\B*2ZYRBFR<=;P5 M)):#YME!$^@,N/LMF6&KP5@Z&&>C/[UI?-0T%9I-& T6A!5?:44.';4D3%(T/H/.UIE?N M#"_0S^3Y#U!+ P04 " H3XQ45"J#0#D" #]! & 'AL+W=OR1E4K-&JIW.$0E>RD+HR,N) MJJGOZR3'DNF!K%"8DTRJDI%1U=;7E4*6.E!9^&$07/DEX\*+9\ZV4O%,UE1P M@2L%NBY+IO8++&03>4/O8'CDVYRLP8]G%=OB&NEKM5)&\WN6E)^GNX0@P"4X P@X0NKS;0"[+6T8LGBG9@++>ALT*KE2' M-LEQ87_*FI0YY09'\9IDLLMED:+2;]],PN'U#=P]U9SV\.X6,YYP>C_SR42R M_G[2L2Y:UO $ZQ4\2$&YACN18OHGWC<9]FF&AS07X5G">]P,()Q<0!B$X1F^ M45_VR/&-3O!U)?Z8;S0ITQD_SW".>\ZQXQS_YZL\RVJ'2QJ!KA+JR M\H<@N C:#X*!68

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end XML 30 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 31 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 61 105 1 false 5 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://cannabics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://cannabics.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://cannabics.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://cannabics.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://cannabics.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business, Presentation and Going Concern Sheet http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcern Nature of Business, Presentation and Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Related Party Transactions Sheet http://cannabics.com/role/RelatedPartyTransactions Related Party Transactions Notes 8 false false R9.htm 00000009 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://cannabics.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 ??? Commitments and Contingencies Sheet http://cannabics.com/role/Note4CommitmentsAndContingencies Note 4 ??? Commitments and Contingencies Notes 10 false false R11.htm 00000011 - Disclosure - Major Events During the six months ended on February 28, 2022 Sheet http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022 Major Events During the six months ended on February 28, 2022 Notes 11 false false R12.htm 00000012 - Disclosure - Subsequent Events Sheet http://cannabics.com/role/SubsequentEvents Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - Nature of Business, Presentation and Going Concern (Policies) Sheet http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies Nature of Business, Presentation and Going Concern (Policies) Policies 13 false false R14.htm 00000014 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative) Sheet http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative Nature of Business, Presentation and Going Concern (Details Narrative) Details http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://cannabics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://cannabics.com/role/RelatedPartyTransactions 15 false false R16.htm 00000016 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative) Sheet http://cannabics.com/role/StockholdersEquityDeficitDetailsNarrative Stockholders??? Equity (Deficit) (Details Narrative) Details http://cannabics.com/role/StockholdersEquityDeficit 16 false false R17.htm 00000017 - Disclosure - Major Events During the six months ended on February 28, 2022 (Details Narrative) Sheet http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022DetailsNarrative Major Events During the six months ended on February 28, 2022 (Details Narrative) Details http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022 17 false false All Reports Book All Reports cnbx_i10q-022822.htm cnbx-20220228.xsd cnbx-20220228_cal.xml cnbx-20220228_def.xml cnbx-20220228_lab.xml cnbx-20220228_pre.xml cnbx_ex3101.htm cnbx_ex3102.htm cnbx_ex3201.htm cnbx_ex3202.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 34 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cnbx_i10q-022822.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 61, "dts": { "calculationLink": { "local": [ "cnbx-20220228_cal.xml" ] }, "definitionLink": { "local": [ "cnbx-20220228_def.xml" ] }, "inline": { "local": [ "cnbx_i10q-022822.htm" ] }, "labelLink": { "local": [ "cnbx-20220228_lab.xml" ] }, "presentationLink": { "local": [ "cnbx-20220228_pre.xml" ] }, "schema": { "local": [ "cnbx-20220228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 167, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 58, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 63 }, "keyCustom": 4, "keyStandard": 101, "memberCustom": 1, "memberStandard": 4, "nsprefix": "CNBX", "nsuri": "http://cannabics.com/20220228", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cannabics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Note 4 \u2013 Commitments and Contingencies", "role": "http://cannabics.com/role/Note4CommitmentsAndContingencies", "shortName": "Note 4 \u2013 Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "CNBX:MajorEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Major Events During the six months ended on February 28, 2022", "role": "http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022", "shortName": "Major Events During the six months ended on February 28, 2022", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "CNBX:MajorEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Subsequent Events", "role": "http://cannabics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Nature of Business, Presentation and Going Concern (Policies)", "role": "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies", "shortName": "Nature of Business, Presentation and Going Concern (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)", "role": "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "shortName": "Nature of Business, Presentation and Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://cannabics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)", "role": "http://cannabics.com/role/StockholdersEquityDeficitDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "span", "p", "CNBX:MajorEventsTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Major Events During the six months ended on February 28, 2022 (Details Narrative)", "role": "http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022DetailsNarrative", "shortName": "Major Events During the six months ended on February 28, 2022 (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "CNBX:MajorEventsTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2022-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "role": "http://cannabics.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2022-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://cannabics.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2022-02-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-12-012022-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-12-012022-02-28", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2020-08-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "role": "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "AsOf2020-08-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://cannabics.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Nature of Business, Presentation and Going Concern", "role": "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcern", "shortName": "Nature of Business, Presentation and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Related Party Transactions", "role": "http://cannabics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Stockholders\u2019 Equity (Deficit)", "role": "http://cannabics.com/role/StockholdersEquityDeficit", "shortName": "Stockholders\u2019 Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-022822.htm", "contextRef": "From2021-09-01to2022-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 5, "tag": { "CNBX_ConvertibleLoanValuation": { "auth_ref": [], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible loan valuation" } } }, "localname": "ConvertibleLoanValuation", "nsuri": "http://cannabics.com/20220228", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_DisclosureMajorEventsDuringSixMonthsEndedOnFebruary282022Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Events During Six Months Ended On February 28 2022" } } }, "localname": "DisclosureMajorEventsDuringSixMonthsEndedOnFebruary282022Abstract", "nsuri": "http://cannabics.com/20220228", "xbrltype": "stringItemType" }, "CNBX_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://cannabics.com/20220228", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "CNBX_HeldForTradingInvestments": { "auth_ref": [], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Held for trading Investments" } } }, "localname": "HeldForTradingInvestments", "nsuri": "http://cannabics.com/20220228", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_MajorEventsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Events During the six months ended on February 28, 2022" } } }, "localname": "MajorEventsTextBlock", "nsuri": "http://cannabics.com/20220228", "presentation": [ "http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022" ], "xbrltype": "textBlockItemType" }, "CNBX_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://cannabics.com/20220228", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r223", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cannabics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r20", "r66", "r176", "r177" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to a related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r15", "r30", "r31", "r32", "r195", "r208", "r209" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r29", "r32", "r38", "r39", "r40", "r67", "r68", "r69", "r157", "r204", "r205", "r232" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r13", "r148", "r182" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r67", "r68", "r69", "r145", "r146", "r147", "r161" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r143", "r144", "r149", "r150" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share based payment" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r123", "r138", "r140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "verboseLabel": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r65", "r89", "r91", "r94", "r100", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r154", "r158", "r164", "r180", "r182", "r187", "r194" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r26", "r65", "r100", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r154", "r158", "r164", "r180", "r182" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r19", "r59" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r54", "r59", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of the Period", "periodStartLabel": "Cash and cash equivalents at beginning of the Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r54", "r165" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (Decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r106", "r107", "r108", "r109", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Note 4 \u2013 Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/Note4CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r67", "r68", "r161" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical", "http://cannabics.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical", "http://cannabics.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r138" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12", "r182" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.0001 par value, 900,000,000 shares authorized, 149,436,681 and 148,661,247 shares issued and outstanding at February 28, 2022 and August 31, 2021 respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r34", "r36", "r37", "r43", "r191", "r202" ], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r63", "r156" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible loan" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r60", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022DetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r60", "r61" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/MajorEventsDuringSixMonthsEndedOnFebruary282022DetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r57", "r104" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r20", "r66", "r113", "r115", "r116", "r120", "r121", "r122", "r175" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r44", "r72", "r73", "r74", "r75", "r76", "r80", "r81", "r83", "r84", "r85", "r86", "r87", "r162", "r163", "r192", "r203" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic and diluted:" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r38", "r39", "r40", "r67", "r68", "r69", "r71", "r77", "r79", "r88", "r101", "r138", "r140", "r145", "r146", "r147", "r152", "r153", "r161", "r166", "r167", "r168", "r169", "r170", "r172", "r204", "r205", "r206", "r232" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r48", "r57", "r97" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Profit from held for trading investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r56" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Royalties receivables valuation" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r56" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Accounts Receivable and pre paid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r199" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Available for sale Investment" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r57" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r65", "r100", "r164", "r182", "r188", "r197" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r65", "r100", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r155", "r158", "r159", "r164", "r180", "r181", "r182" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r54" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from (used) in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r55", "r58" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r33", "r35", "r40", "r41", "r58", "r65", "r70", "r72", "r73", "r74", "r75", "r78", "r79", "r82", "r89", "r90", "r92", "r93", "r95", "r100", "r110", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r121", "r122", "r163", "r164", "r189", "r200" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net (loss)", "verboseLabel": "Net (Loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "http://cannabics.com/role/StatementsOfCashFlows", "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r89", "r90", "r92", "r93", "r95" ], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Nature of Business, Presentation and Going Concern" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r25", "r50" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Issuance of warrants" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r27", "r28", "r30" ], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Profit (loss) from available for sale assets" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r38", "r39", "r42", "r99", "r166", "r171", "r172", "r190", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (loss)" } } }, "localname": "OtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r49" ], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Financial Loss, net." } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r46" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Capital gain", "negatedLabel": "Capital gain" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows", "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r51" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedLabel": "Acquisition of equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11", "r125" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical", "http://cannabics.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11", "r125" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11", "r182" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r102", "r103" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r52" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible loan agreement" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "auth_ref": [ "r53", "r98" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Realization of Available for sale investment" } } }, "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r105", "r182", "r193", "r198" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r151", "r185", "r211" ], "calculation": { "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense", "verboseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r140", "r148", "r182", "r196", "r207", "r209" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets", "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r67", "r68", "r69", "r71", "r77", "r79", "r101", "r145", "r146", "r147", "r152", "r153", "r161", "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r56" ], "calculation": { "http://cannabics.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share based payment" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cannabics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r24", "r38", "r39", "r40", "r67", "r68", "r69", "r71", "r77", "r79", "r88", "r101", "r138", "r140", "r145", "r146", "r147", "r152", "r153", "r161", "r166", "r167", "r168", "r169", "r170", "r172", "r204", "r205", "r206", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r67", "r68", "r69", "r88", "r186" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r23", "r124", "r138", "r139", "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r138", "r140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Exercise of CLA to shares" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock for services, net." } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r16", "r17", "r65", "r96", "r100", "r164", "r182" ], "calculation": { "http://cannabics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets", "http://cannabics.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r64", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r140", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r80", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding - Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://cannabics.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r212": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r213": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r214": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r215": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r216": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r217": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r218": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r219": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r221": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r222": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r223": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r224": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r225": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r226": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r227": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r228": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r229": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r231": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868742-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" } }, "version": "2.1" } ZIP 35 0001683168-22-002526-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-22-002526-xbrl.zip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end